Background: The novel coronavirus named COVID-19, which originated in Wuhan, China, has spread to many countries around the world. Currently, no effective medical treatment exists to combat this disease. Traditional Chinese herbal medicines (CHM) have unique roles in the treatment of viral infections.

Abstract: The coronavirus disease 2019 (COVID-19) is a new infectious disease, firstly appeared in Wuhan city and has rapidly spread to 114 countries outside China, which is receiving worldwide attention. As two important means of examination, computed tomography (CT) and real-time reverse transcription polymerase chain reaction (RT-PCR) have always been controversial in the clinical diagnosis of COVID-19 pneumonia.

Since December 2019, there has been an outbreak of novel coronavirus (2019-nCoV) infection in China, the first case of which was reported in Wuhan, China. On January 19, 2020, the relevant experts and local government officials briefed the public on the 2019-nCoV outbreak.

Background: The emerging infection of the 2019 novel coronavirus (2019-nCoV) in late December, 2019 in Wuhan, China, has caused an extreme health concern, with many patients having progressed to acute respiratory disease or other complications in a short period. Meanwhile, the risk factors associated with the disease progression still remain elusive.

Background: A recent cluster of pneumonia cases in China was caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the screening and diagnosis of corona virus disease 2019 (COVID-19) in our hospital.

Background: The new coronavirus pneumonia (NCP) is now causing a severe public health emergency. The novel coronavirus 2019 (2019-nCoV) infected individuals by binding human angiotensin converting enzyme II (ACE2) receptor. ACE2 is widely expressed in multiple organs including respiratory, cardiovascular, digestive and urinary systems in healthy individuals.

Background: To evaluate the diagnostic efficacy of Densely Connected Convolutional Networks (DenseNet) for detection of COVID-19 features on high resolution computed tomography (HRCT).

Abstract: The “novel” coronavirus disease 2019 (abbreviated “COVID-19”) is the third coronavirus outbreak emerging during the past two decades. This infectious disease, sustained by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has been recently declared a global pandemic by the World Health Organization. Despite the concerning epidemiological burden, many people, including some policymakers, are underestimating this pandemic and are remaining enigmatically inactive against a human pathology which, for a combination of reasons, can be reasonably defined as a perfect storm (i.e., the “wrong virus” at the “wrong time”).

Abstract: It has been over 2 months since the start of the Coronavirus disease 2019 (COVID-19) outbreak. The epidemic stage of COVID-19 has brought great challenges to the diagnosis and management of colorectal cancer (CRC) patients. Symptoms, such as fever and cough caused by cancer, and the therapeutic process (including chemotherapy and surgery) should be differentiated from some COVID-19 related characteristics.

Background: Coronavirus disease 2019 (COVID-19), caused by a novel coronavirus (designated as SARS-CoV-2) has become a pandemic worldwide. Based on the current reports, hypertension may be associated with increased risk of sever condition in hospitalized COVID-19 patients. Angiotensin-converting enzyme 2 (ACE2) was recently identified to functional receptor of SARS-CoV-2.

Background: COVID-19 is currently rampant in China, causing unpredictable harm to humans. This study aimed to quantitatively and qualitatively investigate the research trends on coronaviruses using bibliometric analysis to identify new prevention strategies.

Abstract: Novel coronavirus (2019-nCov) infection (COVID-19) rapidly spread across China and 25 countries in the worldwide, which infected not only adults but also children, even neonates. Each year, about 15 million newborns are delivered in China. Newborn screening (NBS) helps effectively prevent some mental retardation, premature death, and adverse outcomes in the early stage of baby

Abstract: The 2019 novel coronavirus (2019-nCoV) epidemic continues, with the number of infections and deaths increasing. The respiratory tract is the main route of transmission of the virus, and the majority of symptoms are respiratory relative. Until now, there has been no reports concerning the nervous system onset.

Background: The coronavirus disease 2019 (COVID-19) was first identified in Wuhan, China on December 2019 in patients presenting with atypical pneumonia. Although ‘city-lockdown’ policy reduced the spatial spreading of the COVID-19, the city-level outbreaks within each city remain a major concern to be addressed.

Background: The number of patients with pneumonia stemming from the 2019 novel coronavirus (COVID-19) infection has increased rapidly. However, the clinical characteristics of discharged patients remain little known. Here, we attempt to describe the clinical characteristics and treatment experiences of discharged cases from Taizhou, China.

Background: 2019 novel coronavirus disease (COVID-19) has posed significant threats to public health. To identify and treat the severe and critical patients with COVID-19 is the key clinical problem to be solved. The present study aimed to evaluate the clinical characteristics of severe and non-severe patients with COVID-19.

Background: The rapid emergence of clinical trials on COVID-19 stimulated a wave of discussion in scientific community. It is important to understand the characteristics of the ongoing or pending interventional clinical trials on COVID-19.

The COVID-19 outbreak has become a global pandemic within only a few months. COVID-19 patients complicated with severe hypoxemia usually required high-flow nasal cannula (HFNC) and mechanical ventilation. Prone positioning is a salvage therapy for refractory hypoxemia and has proven to be effective in increasing tidal volume and improving oxygenation and diaphragmatic function in patients with acute respiratory distress syndrome (ARDS) (1-3). However, all these studies were conducted in intubated patients.

As of March 13, 2020, the ongoing pandemic of COVID-19 worldwide has caused more than 130,000 infections and the death toll near 5,000. A study of 72,314 Chinese patient records revealed that most cases (80.9%) had mild symptoms while the elderly and people with comorbid conditions such as hypertension and diabetes are at higher risk of severe disease (1).

COVID-19 has become a global hotspot (1,2). We report a case of COVID-19 with no sign of viral pneumonia but initially confirmed as myocarditis by SARS-CoV-2.

On December 8, 2019, the first case of unexplained pneumonia was reported in China, in Wuhan, Hubei Province (1). By March 6, 2020, over 100,000 confirmed cases of coronavirus disease 2019 (COVID-19), and more than 3,400 deaths have been reported worldwide (data from National Health Commission of the People’s Republic of China, Official Channels of Hong Kong, Macao and Taiwan, and World Health Organization). COVID-19, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is bound to have widespread ramifications on the clinical management system, organ transplantation being a prime example.

On January 16, after receiving the kits released by the central government, Hubei Provincial Centers for Disease Control and Prevention began to perform pathogen identification on the specimens obtained from Wuhan patients with viral pneumonia of unknown causes. On January 16–17, the national and provincial expert groups confirmed 4 and 17 2019-nCoV patients, respectively, based on the clinical manifestations, epidemiological histories and pathogen testing results.

Background: According to epidemiological investigation, many cases of coronavirus (COVID-19) pneumonia occurred in Wuhan, Hubei Province, China in December 2019. It is a respiratory infectious disease caused by human-to-human transmission and the host of COVID-19 is likely to be wild animals. On January 23, 2020, the Chinese government adopted emergency management measures to conduct closed management for Wuhan, and 31 provinces, cities and autonomous regions initiated a first-level emergency response, calling on nationals to isolate themselves at home for 14 days.

Background: X-ray imaging is an important method for the diagnosis of the novel coronavirus pneumonia. However, there is a risk of nosocomial infection during X-ray imaging diagnosis.

In this brief letter we would like to refer to you some information about the value of CT imaging for corona virus disease 2019 (COVID-19) pneumonia in cases which have inconsistent COVID-19 nucleic acid test. A 34-year-old man had a 1-day history of fever (39.0 ℃) entered our hospital who resided in Wuhan, China (COVID-19 epicenter) but had traveled to Chengdu, China. The detection of Influenza A, B virus antigens was negative.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerging zoonotic virus that was initially identified in Wuhan City, Hubei Province, China on December 30, 2019 and spread rapidly via human-tohuman transmission chains that existed before containment control measures were implemented.

Background: A new coronavirus pneumonia caused by 2019 new coronavirus (2019-nCoV) is spreading in China. Here we summarized the patients we accepted in the fever outpatient department.

The alarmingly contagious coronavirus disease 2019 (COVID-19) outbreak occurred in Wuhan in December 2019. In response to the call of China’s National Health Commission, the Second Xiangya Hospital (SXYH) of Central South University has sent out 4 teams (with a total of 192 members) to Wuhan to fight directly against the epidemic (1). On February 9, SXYH decided to establish the Front-line Command (FLC) of its National Anti-epidemic Medical Team.

The emergence and spread of a novel coronavirus from Wuhan City, Hubei Province of China, has become a global health concern (1). On 30th January 2020, corona virus disease 2019 (COVID-19) was declared to be a global health emergency by the World Health Organization.

I congratulate Ai et al. for their efforts in analysing a large cohort of corona virus disease 2019 (COVID-19) patients (1). Their results and insights will be helpful for the future in case similar scenario would occur again. However, we need also to re-emphasise the background where and when their data were collected. Their patient data were based in a tertiary hospital in Wuhan and during the period of Jan 6, 2020 to Feb 6, 2020. During this period in Wuhan the attention was mainly paid to the patients with more severe symptoms. While the clinical severity of the patients was not provided in Ai et al.’s paper, it is highly probable that a large proportion of their patients had moderate to severe grades severity.

An ongoing outbreak of a coronavirus disease 2019 (COVID-19) hit major cities of China, Wuhan, late December 2019 and subsequently spread to other areas of China and countries (1). As of February 16, 2020, there were 68594 confirmed cases in mainland China. Among the confirmed cases, approximately 14.0% were severe (2). The mortality rate of severe patients was 6% (3). Herein, we described the clinical characteristics and chest CT follow-up of a severe COVID-19 patient, whose CT appearance was only moderate, and thus represents a case of mismatch between clinical severity and chest imaging severity.

The 2019 novel coronavirus disease (COVID-19) was firstly identified in Wuhan, Hubei Province, China. In China, the data on 29 Feb 2020 showed the fatality rate was 3.6% (2,835/79,251) with most deaths occurred in Wuhan. The fatality rate outside of Hubei province was 0.85% (111/13,052), with seven provinces/regions without death cases (1).

A novel coronavirus named a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sweeping across the entire world rapidly, infecting enormous number of people. Positive real-time reverse transcriptase polymerase chain reaction (RT-PCR) test for SARS-CoV-2 nucleic acid is regarded as the main diagnostic modality for coronavirus disease 2019 (COVID-19) (1). According to the latest Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19), the median time from onset to clinical recovery for mild cases is approximately 2 weeks (2). Currently, there is no available data to predict how long positive SARS-CoV-2 detectability can last in the COVID-19 patients following recovery of clinical symptoms.

In December 2019, a series of pneumonia cases with unknown etiology emerged in Wuhan, Hubei Province of China (1-3). They were later identified to be caused by Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (4). On February 11, 2020, the disease of pneumonia caused by the novel coronavirus was officially named Coronavirus Disease 2019 (COVID-19). By now, the outbreak of COVID-19 has spread rapidly to more than 150 countries worldwide.

In December 2019, several cases of “unknown viral pneumonia” were reported in Wuhan City, Hubei Province, China (1). It was named as the 2019 novel coronavirus disease (COVID-19) by the World Health Organization (WHO) (1). In just two months, the virus has spread from Wuhan to other parts of China, and all over the world. By 24:00 on March 8,

The emergence and spread of a novel coronavirus (2019-nCoV) from Wuhan City, Hubei Province of China, has become a global health concern (1). Since the detection of the coronavirus in late December 2019, sporadic imported cases among travelers returning from Wuhan and human-to-human transmission have been reported in several non-Wuhan/non-Hubei areas (2,3). We describe the CT features of one family cluster of 2019-nCoV.

Background: Since December 2019, a number of patients infected with COVID-19 (SARS-CoV-2) have been identified in Wuhan, Hubei, China. As the epidemic has spread, similar cases have also been found in other parts of mainland China and abroad. The main reason for this spread is the highly contagious nature of the virus and the fact that children can also become infected during its incubation period. This has made the virus a substantial challenge for the outpatient triage staff of children’s hospitals outside the epidemic area of the Hubei Province. It is very important for the preview and triage personnel to accurately grasp the epidemiology of the virus and identify children’s symptoms in the fever clinic.

Backgrounds: Our study aimed to explore the anxiety levels and possible associated factors in the pediatric medical staff in Jiangsu province during an outbreak of Coronavirus Disease 2019 (COVID-19).
Methods: Pediatric medical staff (n=534) from nine hospitals in Jiangsu province were enrolled. Theiranxiety levels and quality of sleep were assessed using the online SAS and PSQI questionnaires.

Background: The coronavirus disease 2019 (COVID-19) outbreak originating in Wuhan, Hubei province, China, coincided with chunyun, the period of mass migration for the annual Spring Festival. To contain its spread, China adopted unprecedented nationwide interventions on January 23, 2020.

Recently, a new coronavirus disease (COVID-19) has emerged as a respiratory infection with significant concern for global public health hazards. With an initial suspicion of the animal to the human transmission for earlier cases, now the paradigm has shifted towards human to human transmission via droplets, contacts and/or through fomites. with each passing day, more and more confirmed cases are being reported worldwide which has alarmed the global authorities including World Health Organization (WHO)

In December 2019, a new type of Coronavirus that causes pneumonia was first detected in Wuhan, China, and is since then spreading worldwide.

Backgrounds: An ongoing outbreak of pneumonia caused by a novel coronavirus [severe acute respiratory syndrome coronavirus (SARS-CoV)-2], named COVID-19, hit a major city of China, Wuhan in December 2019 and subsequently spread to other provinces/regions of China and overseas. Several studies have been done to estimate the basic reproduction number in the early phase of this outbreak, yet there are no reliable estimates of case fatality rate (CFR) for COVID-19 to date.

Since the first cases of pneumonia of an unknown origin were identified in Wuhan, the capital city of Hubei province, China in December 2019, Chinese scientists have urgently and persistently worked to determine the causative agent.

The coronavirus disease 2019 (COVID-19) from Wuhan, China has become a global challenge since the late December 2019.

Since December, 2019, a 2019 novel coronavirus disease (COVID-19) infected by the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) emerged in Wuhan, Hubei province, and the epidemic situation has continued to spread globally.

In December 2019, the 2019 novel coronavirus (2019-nCoV) was identified in the viral pneumonia cases occurredin Wuhan, Hubei Province, China; In the following month,the 2019-nCoV quickly spreading inside and outside of Hubei Province and even other countries. Respiratory droplet transmission is the main route of transmission, while it can also be transmitted through contact.

Background: The newly identified 2019-nCoV, which appears to have originated in Wuhan, the capitalcity of Hubei province in central China, is spreading rapidly nationwide. A number of cases of neonates born to mothers with 2019-nCoV pneumonia have been recorded. However, the clinical features of these cases have not been reported, and there is no sufficient evidence for the proper prevention and control of 2019-nCoV infections in neonates.

Two decades after the severe acute respiratory syndrome (SARS), and one decade after the middle east respiratory syndrome (MERS), a new outbreak of respiratory illness sustained by a member of the coronavirus (CoV) family has been first identified in Wuhan (Hubei Province, China), and is rapidly spreading around the world.

Since December 2019, there has been an outbreak of novel coronavirus (2019-nCoV) infectionin China. Two cases of neonates with positive 2019-nCoV tests have been reported.